Amgen scores EU nod for UPLIZNA in rare autoimmune disease
The approval marks a major advance in targeted treatment for this rare, chronic autoimmune disease, offering twice-yearly maintenance dosing after two initial loading doses
The approval marks a major advance in targeted treatment for this rare, chronic autoimmune disease, offering twice-yearly maintenance dosing after two initial loading doses
Bocunebart works by blocking pituitary adenylate cyclase-activating polypeptide
Achondroplasia is a genetic condition driven by FGFR3 that affects more than stature alone
PiNACLE is a head-to-head study comparing its next-generation CAR T-cell therapy against established therapies liso-cel and axi-cel in patients with relapsed or refractory large B-cell lymphoma
This approval represents the seventh FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx with KEYTRUDA
Operational leverage kicked in during the quarter, with adjusted EBITDA rising 21% year-on-year to Rs 147 crore
PBGENE-DMD is designed to permanently correct mutations in the dystrophin gene between exons 45 and 55, the “hot-spot” region affecting roughly 60% of DMD patients
Garijo will be the first woman to lead Sanofi in its history
KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to its components
The program provides pharmaceutical manufacturers with auditable, primary emissions data and verified proof of a 30% CO? reduction across DFE Pharma’s lactose portfolio
Subscribe To Our Newsletter & Stay Updated